Loading
Found that leukaemias depend on the chromatin reader BRD4, launching BET inhibitors, and mapped transcriptional addictions in sarcoma.
Christopher R. Vakoc is Professor at the Cold Spring Harbor Laboratory Cancer Center, where he studies transcriptional dependencies in cancer. He is known for finding through an RNA interference screen that acute myeloid leukaemia depends on the chromatin reader BRD4, work that launched BET inhibitors, and for developing CRISPR domain-scanning to find druggable protein domains. His selected paper reports the RNAi screen identifying Brd4 as a therapeutic target in AML. His laboratory now maps transcriptional addictions in Ewing sarcoma and rhabdomyosarcoma using CRISPR functional genomics.
| Title | Journal | Year |
|---|---|---|
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Nature | 2011 |
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, CRISPR functional genomics, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares CRISPR functional genomics, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, CRISPR functional genomics, Sarcomas (soft tissue, bone, GIST).
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.